Secondary analysis of the SONIA trial in advanced breast cancer: health-related quality of life did not differ clinically or statistically between first-line and second-line CDK4/6 inhibitor use (FACT-B mean difference -0.66, P=.39).
Secondary analysis
Wortelboer et al. Health-related quality of life with first- vs second-line CDK4/6 inhibitor use in advanced breast cancer: results from the SONIA trial